Since the loss of p16 (CDKN2A) expression has been associated with sensitivity to the CDK4/6 inhibitor palbociclib in melanoma cell lines [35] and breast cancer patient [36], we further investigated p16 RNA and protein expression in metastatic lung lesion and PDX-mlung. This evidence concerns the gene CDK4 and breast cancer.